Hemispherx Ampligen Filing Will Jumpstart NDA Clock
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma accelerates evaluation of the Toll-like receptor-3 agonist as an adjuvant for HIV/AIDS and avian influenza vaccines.
You may also be interested in...
Merck, NIH Cannot Explain Higher Number Of AIDS Cases In HIV Vaccinated Individuals
In some instances, the vaccine may have led to an increase in HIV infections.
Hemispherx Submits NDA For First-Ever Chronic Fatigue Syndrome Therapy
Complete Ampligen NDA was submitted to FDA Oct. 10, CEO Carter tells “The Pink Sheet” DAILY.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.